Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Limited clinical relevance of mitochondrial DNA mutation and gene expression analyses in ovarian cancer.
PMID 18842121 · PMC2571110 · BMC cancer · 2008 · 8 claims · 2 setups
Somatic mutations in the mtDNA D-loop are found in 57% of ovarian cancer samples, mostly C-tract length changes and substitutions
-
Full-text index only
The human homologue of unc-93 maps to chromosome 6q27 - characterisation and analysis in sporadic epithelial ovarian cancer.
PMID 12381271 · PMC134458 · BMC genetics · 2002 · 7 claims · 8 setups
UNC93A maps within the minimal region of allele loss on 6q27 between D6S264 and D6S149, centromeric to D6S149
-
Full-text index only
Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas.
PMID 11161400 · PMC2363740 · British journal of cancer · 2001 · 7 claims · 7 setups
Id3 mRNA and protein expression are decreased in ovarian cancer cell lines compared to immortalized HOSE cells
-
Full-text index only
sCellST predicts single-cell gene expression from H& E images.
PMID 41513659 · PMC12858858 · Nature communications · 2026 · 7 claims · 6 setups
sCellST is a weakly supervised (Multiple Instance Learning) deep learning framework that predicts single-cell gene expression from H&E images alone, trained using paired spatial transcriptomics (Visium) and H&E slides
-
Full-text index only
MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
PMID 19798417 · PMC2749450 · PloS one · 2009 · 7 claims · 7 setups
High grade serous carcinomas with and without BRCA1/2 abnormalities show very similar miRNA expression profiles, with no clear clustering separation by BRCA1/2 status
-
Has reproduction · 75
Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.
PMID 34143800 · PMC8213194 · PloS one · 2021 · 8 claims · 7 setups
306 overlapping DEGs (265 up-regulated, 41 down-regulated) were identified from three independent GEO microarray datasets comparing EOC and adjacent normal ovarian tissue
-
Full-text index only
Proteomics: characterizing the cogs in the machinery of life.
PMID 14630521 · PMC1241753 · Environmental health perspectives · 2003 · 8 claims · 5 setups
Protein expression patterns in blood serum, detected via SELDI-TOF mass spectrometry and analyzed with a genetic algorithm, can distinguish ovarian cancer patients from healthy individuals with very high sensitivity and specificity.
-
Full-text index only
Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
PMID 19010816 · PMC6953412 · Molecular cancer research : MCR · 2008 · 8 claims · 8 setups
Activating RAS-MAPK pathway mutations are present in >70% of serous LMP tumors versus ~12.5% of serous ovarian carcinomas
-
Full-text index only
SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.
PMID 41807550 · PMC13249849 · NPJ precision oncology · 2026 · 8 claims · 8 setups
MCL1 inhibition is synthetic lethal with SMARCA4/2 loss in SCCOHT and NSCLC cells
-
Full-text index only
A transcriptomic-based model associated with PARP inhibitor sensitivity and immunogenic signatures in ovarian cancer.
PMID 42014663 · PMC13230468 · Discover oncology · 2026 · 8 claims · 8 setups
A 23-gene PARPi-sensor transcriptomic model stratifies ovarian cancer patients into high- and low-risk groups with significantly different overall survival, validated in TCGA and ICGC cohorts
-
Has reproduction · 77
Metabolic reprogramming and prognostic insights in molecular landscapes driven by glycolysis in ovarian cancer.
PMID 40707588 · PMC12290113 · Scientific reports · 2025 · 7 claims · 8 setups
457 differentially expressed GRGs were identified between OC and normal ovarian tissue, of which 30 were significantly associated with prognosis
-
Full-text index only
Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression.
PMID 8956789 · PMC2077203 · British journal of cancer · 1996 · 8 claims · 4 setups
GSTM1, GSTT1 and CYP2D6 genotype/allele frequencies did not differ significantly between 84 ovarian cancer cases and 325 controls, showing no association with disease susceptibility.
-
Full-text index only
Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy.
PMID 15601541 · PMC3525069 · Human genomics · 2004 · 8 claims · 6 setups
DNA microarray gene expression profiling generates robust molecular classifications for many tumour types (brain, breast, colon, gastric, kidney, leukaemia, lymphoma, lung, melanoma, ovary, prostate, etc.)
-
Full-text index only
Proteomics as a tool for biomarker discovery.
PMID 18057524 · PMC3851415 · Disease markers · 2007 · 8 claims · 7 setups
A useful clinical biomarker must be easily attainable, have adequate sensitivity, have adequate specificity, and lead to patient benefit through intervention
-
Full-text index only
Contribution of oncoproteomics to cancer biomarker discovery.
PMID 17407558 · PMC1852117 · Molecular cancer · 2007 · 6 claims · 8 setups
Oncoproteomic biomarker panels (2-DE/MS-based) show higher sensitivity and specificity than currently used single tumor markers across multiple cancer types (Table 1)
-
Full-text index only
Ovarian cancer biomarkers: current options and future promise.
PMID 18926090 · PMC3381792 · Journal of the National Comprehensive Cancer Network : JNCCN · 2008 · 8 claims · 8 setups
CA125 lacks the sensitivity and specificity needed for reliable early-stage ovarian cancer detection, since only ~50% of stage I/II cases show elevated levels
-
Full-text index only
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
PMID 19654294 · PMC2754824 · Cancer research · 2009 · 8 claims · 7 setups
Secondary BRCA2 mutations restore BRCA2 protein/reading frame and thereby cause acquired platinum and PARP inhibitor resistance in BRCA2-mutated ovarian carcinoma
-
Full-text index only
Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors.
PMID 15836779 · PMC1112590 · BMC genomics · 2005 · 8 claims · 3 setups
A custom 60-mer oligonucleotide microarray covering 3531 secreted and cell surface genes was designed to profile 5 transformed human cell lines and their derivative xenograft tumors.
-
Has reproduction · 87
CoINcIDE: A framework for discovery of patient subtypes across multiple datasets.
PMID 26961683 · PMC4784276 · Genome medicine · 2016 · 8 claims · 4 setups
CoINcIDE is a novel framework for discovering patient subtypes across multiple datasets that requires no between-dataset transformations (e.g., batch correction)
-
Full-text index only
Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression.
PMID 7669582 · PMC2033876 · British journal of cancer · 1995 · 8 claims · 5 setups
A novel missense mutation (TGG→CGG, Trp133→Arg) in nm23-H2 was found in one stage III serous ovarian carcinoma